Return on Tangible Equity (Quarterly)

Return on Tangible Equity: The amount of net income returned as a percentage of shareholders equity, after subtracting intangible assets, goodwill and preferred equity. Calculated as: Income from Continuing Operations / Tangible Shareholders Equity

West Pharmaceutical Services, Inc. (WST) had Return on Tangible Equity of 4.83% for the most recently reported fiscal quarter, ending 2026-03-31.

Quarterly Annual

Figures for fiscal quarter ending 2026-03-31

Income Statement Financials
Revenue	$844.90M
Net Income	$138.80M
Cost of Goods Sold	$548.50M
Gross Profit	$296.40M
Operating Expenses	$667.80M
Operating Income	$177.10M
Non-Operating Income/Expense	$3.00M
Pre-Tax Income	$180.10M
Normalized Pre-Tax Income	$180.10M
Income after Taxes	$135.40M
Income from Continuous Operations	$138.80M
Consolidated Net Income/Loss	$138.80M
Normalized Income after Taxes	$135.40M
EBIT	$177.10M
EBITDA	$222.30M
Weighted-Average Shares Outstanding (Basic)	72.00M
Weighted-Average Shares Outstanding (Diluted)	72.40M
Earnings per Share (EPS) (Basic)	$1.93
Earnings per Share (EPS) (Diluted)	$1.92
Balance Sheet Financials
Current Assets	$1.83B
Property, Plant, and Equipment	$1.70B
Long-Term Assets	$2.28B
Total Assets	$4.11B
Current Liabilities	$674.00M
Long-Term Debt	$202.80M
Long-Term Liabilities	$445.40M
Total Liabilities	$1.12B
Common Equity	$2.99B
Tangible Shareholders Equity	$2.87B
Shareholders Equity	$2.99B
Common Shares Outstanding	70.90M
Cash Flow Statement Financials
Cash Flow from Operating Activities	$89.90M
Cash Flow from Investing Activities	$-42.70M
Cash Flow from Financial Activities	$-308.70M
Beginning Cash	$791.30M
End Cash	$521.40M
Increase/Decrease in Cash	$-269.90M
Stock-Based Compensation	$6.60M
Common Stock Dividends Paid	$-15.80M
Preferred Stock Dividends Paid	--
Fundamental Metrics & Ratios
Current Ratio	2.71
Non-Performing Assets / Total Loans	--
Loan Loss Reserves / Non-Performing Loans	--
Debt to Capital Ratio	0.06
Debt to Equity Ratio	0.07
Gross Margin	35.08%
Operating Margin	20.96%
EBIT Margin	20.96%
EBITDA Margin	--
Pre-Tax Profit Margin	21.32%
Profit Margin	16.43%
Free Cash Flow	$47.20M
Loss Ratio	--
Expense Ratio	--
Combined Ratio	--
Asset Turnover	0.21
Inventory Turnover	1.21
Receiveable Turnover	1.23
Days Sales in Receivables	73.03
Return on Equity	4.64%
Return on Tangible Equity	4.83%
Return on Assets	3.38%
Return on Investments	4.35%
Book Value Per Share	$42.18
Free Cash Flow per Share	$0.65
Operating Cash Flow per Share	$1.24

Data from Zacks Investment Research, Inc.